article
21 September 2015 | By David Britton (Barts Cancer Institute), Manfred Raida (National University of Singapore), Pedro Cutillas (Barts Cancer Institute)
In this Proteomics In-Depth Focus: David J. Britton & Pedro R. Cutillas from Barts Cancer Institute ask should LC-MS/MS proteomics guide targeted drug selection for cancer patients? And Manfred Raida from the National University of Singapore explains how mass spectrometry and drug development come together...